Cubist Leadership Transitions To Perez With ‘Strong Hand To Play’
This article was originally published in The Pink Sheet Daily
Executive Summary
President and Chief Operating Officer Robert Perez will succeed Michael Bonney as CEO effective Jan. 1, taking over the top leadership spot at a time when the specialty pharma is in the midst of a transformation into a multi-asset company.